+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials), by Indication, by Region, and Segment Forecasts, 2021-2028

  • PDF Icon

    Report

  • 100 Pages
  • June 2021
  • Region: Global
  • Grand View Research
  • ID: 5390538
Description Jump to:
The global immuno-oncology clinical trials market size is expected to reach USD 15.1 billion by 2028. The market is expected to expand at a CAGR of 13.6% from 2021 to 2028. The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.

From 2014 to 2017, the number of new immuno-oncology studies increased from 250 to almost 600, with double-digit growth rates each year as drug classes diversified. Biomarker and checkpoint inhibitor studies were primarily responsible for this rapid growth. While the immuno-oncology market is maturing in some pharmacological classes, cell therapies are exceeding all other immunotherapeutics in terms of growth. In March 2020, there were 1,483 active compounds in the pipeline for cancer cell therapy globally, indicating an increase of 472 from March 2019. The fastest-growing category was chimeric antigen receptor T (CAR-T) cell products (up 77% from 2019 to 2020).

Besides, during the Covid-19 pandemic, the number of IO drugs in development increased from 3,876 in 2019 to 4,720 in 2020, representing a 22% & 233% increase as compared to 2019 & 2017 respectively. After a moderate increase of 15% in 2019 compared to 68% between 2018 and 2017, this 22% increase indicates a return of interest in IO, despite the impact of the COVID-19 pandemic.

Immuno-oncology Clinical Trials Market Report Highlights

  • Phase III dominated the market with the largest share of 53.2% in 2020. In 2019, 29.0% of Phase III drugs have a higher-than-average chance of approval, up from 24.2% in 2018
  • The interventional experiments accounted for more than 78.6% of the market share in 2020
  • The segment of solid tumors held 56.0% of the revenue share in 2020. This is largely attributed to the rise in the prevalence of solid tumors
  • North America dominated the market and accounted for the largest revenue share of 51.0% in 2020. This is due to the rising adoption of personalized medicine-focused novel treatment methods, as well as the government funding and investments
  • Asia Pacific is expected to register the fastest growth rate of 14.7% over the forecast period. At the end of 2019, over 40.0% of current immuno-oncology clinical experiments involved at least one location in the region


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region Wise Market Calculation
1.6.1 Region Wise Market: Base Estimates
1.6.2 Global Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1: Understanding market dynamics
1.8.2 Objective - 2: Understanding market estimates and forecasts
1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
1.8.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size.
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Market Segment Outlook
2.3 Market Competitive Insight
Chapter 3 Immuno-oncology clinical trials Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing number of cancer cases due to lifestyle changes
3.2.1.2 Increasing demand for personalized medicines
3.2.1.3 Recent developments in immuno-oncology
3.2.1.4 The growing acceptability of targeted therapy
3.2.2 Market Restraint Analysis
3.2.2.1 Requirement of high capital investments and low cost-benefit ratio
3.3 Penetration & Growth Prospect Mapping
3.4 COVID-19 Impact on the Market
3.5 Major Deals and Strategic Alliances Analysis
3.6 Immuno-oncology Clinical Trials: Market Analysis Tools
3.6.1 Industry Analysis - Porter’s
3.6.2 PESTEL Analysis
Chapter 4 Immuno-oncology Clinical Trials Market: Phase Segment Analysis
4.1 Immuno-oncology Clinical Trials Market: Phase Market Share Analysis, 2020 & 2028
4.2 Phase I
4.2.1 Phase I Market, 2016 - 2028 (USD Million)
4.3 Phase II
4.3.1 Phase II Market, 2016 - 2028 (USD Million)
4.4 Phase III
4.4.1 Phase III Market, 2016 - 2028 (USD Million)
4.5 Phase IV
4.5.1 Phase IV, 2016 - 2028 (USD Million)
Chapter 5 Immuno-oncology Clinical Trials Market: Design Segment Analysis
5.1 Immuno-oncology Clinical Trials Market: Design Market Share Analysis, 2020 & 2028
5.2 Interventional Trials
5.2.1 Interventional Trials Immuno-oncology Clinical Trials market, 2016 - 2028 (USD Million)
5.3 Observational Trials
5.3.1 Observational Trials Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
5.4 Expanded access Trials
5.4.1 Expanded Access Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
Chapter 6 Immuno-oncology Clinical Trials Market: Indication Segment Analysis
6.1 Immuno-oncology Clinical Trials Market: Indication Market Share Analysis, 2020 & 2028
6.2 Solid Tumors
6.2.1 Solid Tumors Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
6.3 Hematological Cancer
6.3.1 Hematological Cancer Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
Chapter 7 Immuno-oncology Clinical Trials Market: Regional Analysis
7.1 Immuno-oncology Clinical Trials Market: Regional Market Share Analysis, 2020 & 2028
7.2 North America
7.2.1 North America Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3 Europe
7.3.1 Europe Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.2 U.K.
7.3.2.1 U.K. Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.4 France
7.3.4.1 France Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.5 Italy
7.3.5.1 Italy Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.6 Spain
7.3.6.1 Spain Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.3 China
7.4.3.1 China Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.4 India
7.4.4.1 India Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.5 Singapore
7.4.5.1 Singapore Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.6 Thailand
7.4.6.1 Thailand Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5 Latin America
7.5.1 Latin America Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5.5 Colombia
7.5.5.1 Colombia Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.6 MEA
7.6.1 MEA Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
7.6.4 UAE
7.6.4.1 UAE Immuno-oncology Clinical Trials Market, 2016 - 2028 (USD Million)
Chapter 8 Company Profiles
8.1 ICON, Plc
8.1.1 Company Overview
8.1.2 Service Benchmarking
8.1.3 Financial Performance
8.1.4 Strategic Initiatives
8.2 IQVIA Holdings
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Service Benchmarking
8.2.4 Strategic Initiatives
8.3 BioNtech
8.3.1 Company Overview
8.3.2 Service Benchmarking
8.3.3 Strategic Initiatives
8.4 Covance, Inc.
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Service Benchmarking
8.5 IO BIOTECH
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Service Benchmarking
8.6 MEDPACE
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Service Benchmarking
8.7 Exscientia
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Service Benchmarking
8.7.4 Strategic Initiatives
8.8 Syneous Health
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Service Benchmarking
8.9 Astrazeneca
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Service Benchmarking
8.9.4 Strategic Initiatives
8.9.5 Strategic Initiatives
8.10 Novartis
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Service Benchmarking
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Immuno-oncology Clinical Trials Market, by region, 2016 - 2028 (USD Million)
Table 4 Global Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 5 Global Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 6 Global Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 7 North America Immuno-oncology Clinical Trials Market, by Country, 2016 - 2028 (USD Million)
Table 8 North America Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 9 North America Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 10 North America Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 11 U.S. Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 12 U.S. Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 13 U.S. Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 14 Canada Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 15 Canada Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 16 Canada Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 17 Europe Immuno-oncology Clinical Trials Market, by Country, 2016 - 2028 (USD Million)
Table 18 Europe Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 19 Europe Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 20 Europe Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 21 U.K. Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 22 U.K. Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 23 U.K. Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 24 Germany Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 25 Germany Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 26 Germany Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 27 France Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 28 France Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 29 France Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 30 Italy Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 31 Italy Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 32 Italy Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 33 Spain Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 34 Spain Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 35 Spain Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 36 Asia Pacific Immuno-oncology Clinical Trials Market, by Country, 2016 - 2028 (USD Million)
Table 37 Asia Pacific Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 38 Asia Pacific Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 39 Asia Pacific Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 40 Japan Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 41 Japan Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 42 Japan Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 43 China Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 44 China Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 45 China Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 46 India Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 47 India Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 48 India Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 49 Thailand Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 50 Thailand Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 51 Thailand Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 52 Singapore Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 53 Singapore Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 54 Singapore Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 55 Latin America Immuno-oncology Clinical Trials Market, by Country, 2016 - 2028 (USD Million)
Table 56 Latin America Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 57 Latin America Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 58 Latin America Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 59 Brazil Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 60 Brazil Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 61 Brazil Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 62 Argentina Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 63 Argentina Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 64 Argentina Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 65 Mexico Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 66 Mexico Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 67 Mexico Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 68 Colombia Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 69 Colombia Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 70 Colombia Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 71 Middle East & Africa Immuno-oncology Clinical Trials Market, by Country, 2016 - 2028 (USD Million)
Table 72 Middle East & Africa Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 73 Middle East & Africa Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 74 Middle East & Africa Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 75 South Africa Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 76 South Africa Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 77 South Africa Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 78 South Arabia Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 79 South Arabia Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 80 South Arabia Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
Table 81 UAE Immuno-oncology Clinical Trials Market, by Phase, 2016 - 2028 (USD Million)
Table 82 UAE Arabia Immuno-oncology Clinical Trials Market, by Design, 2016 - 2028 (USD Million)
Table 83 UAE Arabia Immuno-oncology Clinical Trials Market, by Indication, 2016 - 2028 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Secondary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Immuno-oncology clinical trials market snapshot (2020)
Fig. 9 Immuno-oncology clinical trials market segmentation
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Porter’s five forces analysis
Fig. 14 PESTEL analysis
Fig. 15 Immuno-oncology clinical trials market phase outlook: Segment dashboard
Fig. 16 Immuno-oncology clinical trials market: Phase movement analysis
Fig. 17 Phase I market, 2016 - 2028 (USD Million)
Fig. 18 Phase II market, 2016 - 2028 (USD Million)
Fig. 19 Phase III market, 2016 - 2028 (USD Million)
Fig. 20 Phase IV market, 2016 - 2028 (USD Million)
Fig. 21 Immuno-oncology clinical trials design outlook: Segment dashboard
Fig. 22 Immuno-oncology clinical trials market: Design movement analysis
Fig. 23 Interventional based Immuno-oncology clinical trials market, 2016 - 2028 (USD Million)
Fig. 24 Observational based Immuno-oncology clinical trials market, 2016 - 2028 (USD Million)
Fig. 25 Expanded access based Immuno-oncology clinical trials market, 2016 - 2028 (USD Million)
Fig. 26 Immuno-oncology clinical trials market indication outlook: Segment dashboard
Fig. 27 Immuno-oncology clinical trials market: Indication movement analysis
Fig. 28 Solid tumors based Immuno-oncology clinical trials market, 2016 - 2028 (USD Million)
Fig. 29 Hematological cancer based Immuno-oncology clinical trials market, 2016 - 2028 (USD Million)
Fig. 30 Regional market: Key takeaways
Fig. 31 Regional outlook, 2020 & 2028
Fig. 32 North America market, 2016 - 2028 (USD Million)
Fig. 33 U.S. market, 2016 - 2028 (USD Million)
Fig. 34 Canada market, 2016 - 2028 (USD Million)
Fig. 35 Europe market, 2016 - 2028 (USD Million)
Fig. 36 U.K. market, 2016 - 2028 (USD Million)
Fig. 37 Germany market, 2016 - 2028 (USD Million)
Fig. 38 France market, 2016 - 2028 (USD Million)
Fig. 39 Italy market, 2016 - 2028 (USD Million)
Fig. 40 Spain market, 2016 - 2028 (USD Million)
Fig. 41 Asia Pacific market, 2016 - 2028 (USD Million)
Fig. 42 Japan market, 2016 - 2028 (USD Million)
Fig. 43 China market, 2016 - 2028 (USD Million)
Fig. 44 India market, 2016 - 2028 (USD Million)
Fig. 45 Singapore market, 2016 - 2028 (USD Million)
Fig. 46 Thailand market, 2016 - 2028 (USD Million)
Fig. 47 Latin America market, 2016 - 2028 (USD Million)
Fig. 48 Brazil market, 2016 - 2028 (USD Million)
Fig. 49 Mexico market, 2016 - 2028 (USD Million)
Fig. 50 Argentina market, 2016 - 2028 (USD Million)
Fig. 51 Colombia market, 2016 - 2028 (USD Million)
Fig. 52 MEA market, 2016 - 2028 (USD Million)
Fig. 53 South Africa market, 2016 - 2028 (USD Million)
Fig. 54 Saudi Arabia market, 2016 - 2028 (USD Million)
Fig. 55 UAE market, 2016 - 2028 (USD Million)

Companies Mentioned

  • ICON, Plc
  • IQVIA Holdings
  • BioNtech
  • Covance, Inc.
  • IO BIOTECH
  • MEDPACE
  • Exscientia
  • Syneous Health
  • Astrazeneca
  • Novartis

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedJune 2021
Forecast Period2021 - 2028
Estimated Market Value ( USD ) in 2021 $ 6.2 billion
Forecasted Market Value ( USD ) by 2028 $ 15.1 billion
Compound Annual Growth Rate13.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Forecast 2024-2030 - Product Image

Global Immuno-oncology Clinical Trials Market by Design (Expanded Access Trials, Interventional Trials, Observational Trials), Phase (Phase I, Phase II, Phase III), Indication - Forecast 2024-2030

  • Report
  • 197 Pages
  • Global
From
Immuno-Oncology Clinical Trials Market Report 2023-2033 - Product Image

Immuno-Oncology Clinical Trials Market Report 2023-2033

  • Report
  • 249 Pages
  • Global
From
Immuno-Oncology - Thematic Intelligence - Product Image

Immuno-Oncology - Thematic Intelligence

  • Report
  • 169 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 178 Pages
  • Global
From
Immuno-Oncology Drug Development: Analytical Tool - Product Image

Immuno-Oncology Drug Development: Analytical Tool

  • Report
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.